|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 175.84 USD | -2.55% |
|
-2.41% | +14.99% |
Business description: Biogen Inc.
- sales of medicines (74.6%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (6.7%) ;
- other (18.7%): primarily revenues from partnership agreements.
Number of employees: 7,605
Sales by Activity: Biogen Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Discovering, Developing and Delivering Innovative Therapies | 13.44B | 10.98B | 10.17B | 9.84B | 9.68B |
Geographical breakdown of sales: Biogen Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States (U.S.) | 8.53B | 5.83B | 5.53B | 5.43B | 5.31B |
Europe | - | 2.64B | 2.41B | 2.14B | 2.17B |
Germany | - | 1.16B | 926M | 868M | 956M |
Asia | 630M | 725M | 720M | 863M | 624M |
Other | 619M | 627M | 583M | 531M | 558M |
Europe (Incl. Germany) | 3.66B | - | - | - | - |
Executive Committee: Biogen Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2022-11-13 | |
Robin Kramer
DFI | Director of Finance/CFO | 59 | 2025-02-28 |
Nicole Murphy
COO | Chief Operating Officer | - | 2022-01-31 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 58 | 2023-10-01 |
Priya Singhal
CTO | Chief Tech/Sci/R&D Officer | 57 | 2024-03-14 |
Composition of the Board of Directors: Biogen Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Caroline Dorsa
CHM | Chairman | 65 | 2023-06-25 |
Eric Rowinsky
BRD | Director/Board Member | 68 | 2010-03-22 |
Stephen Sherwin
BRD | Director/Board Member | 76 | 2009-12-31 |
William Hawkins
BRD | Director/Board Member | 71 | 2019-06-18 |
Jesus Mantas
BRD | Director/Board Member | 56 | 2019-06-18 |
Maria Freire
BRD | Director/Board Member | 70 | 2021-06-01 |
| Director/Board Member | 65 | 2022-11-13 | |
Susan Langer
BRD | Director/Board Member | 34 | 2023-06-25 |
| Director/Board Member | 55 | 2023-12-31 | |
Lloyd Minor
BRD | Director/Board Member | 67 | 2024-09-30 |
Holdings: Biogen Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
DENALI THERAPEUTICS INC. 4.88% | 7,155,243 | 4.88% | 139,312,581 $ |
| 3,250,000 | 0.97% | 1,498,250 $ |
Company details: Biogen Inc.
Group companies: Biogen Inc.
| Name | Category and Sector |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. Develops and manufactures drugs related to immunology, neurobiology and oncology | |
Biogen MA, Inc.
Biogen MA, Inc. Develops and manufactures drugs related to immunology, neurobiology and oncology | |
Biogen Belgium NV/SA
 Biogen Belgium NV/SA BiotechnologyHealth Technology Operates as a biotechnology company |
Biotechnology
|
Biogen Belgium NV/SA
Biogen Belgium NV/SA BiotechnologyHealth Technology Operates as a biotechnology company |
Biotechnology
|
Tokheim Belgium NV (Belgium) |
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.55% | -2.41% | +12.39% | -38.38% | 26.47B | |
| -1.52% | -6.66% | -12.11% | -7.66% | 72.15B | |
| -0.67% | -0.93% | -35.96% | -39.43% | 59.28B | |
| -2.42% | -0.33% | +33.08% | +237.98% | 54.78B | |
| +1.90% | +66.00% | +66.00% | +66.00% | 51.37B | |
| -1.59% | -6.19% | +31.97% | +15.57% | 18.98B | |
| +0.47% | -7.57% | +122.41% | +165.16% | 18.86B | |
| -0.22% | -12.28% | +60.35% | +1,013.28% | 16.69B | |
| -3.46% | +0.29% | +142.95% | +706.19% | 14.31B | |
| -0.04% | -.--% | +55.21% | +154.72% | 14.02B | |
| Average | -0.39% | -3.61% | +47.63% | +227.34% | 34.69B | |
| Weighted average by Cap. | -0.40% | -2.85% | +26.71% | +130.03% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
- Company Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
